•
AU
AUTL
Autolus Therapeutics plc American Depositary Share
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
391.23M
Volume
1.41M
52W High
$2.70
52W Low
$1.11
Open
$0.00
Prev Close
$1.42
Day Range
0.00 - 0.00
About Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Latest News
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
GlobeNewswire Inc.•Nov 25
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
GlobeNewswire Inc.•Oct 27
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
GlobeNewswire Inc.•Oct 20
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire Inc.•Aug 12
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewswire Inc.•Jul 21
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
GlobeNewswire Inc.•Apr 22
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.•Apr 2
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
GlobeNewswire Inc.•Mar 6